Brief: Can-Fite Namodenoson Inhibits Pancreatic Cancer In Preclinical Studies—A Patent Has Been Filed

Can Fite Biopharma

24/01/2023 12:04

Jan 24 (Reuters) - Can Fite BioPharma Ltd  CANF.TA :
    * CAN-FITE: NAMODENOSON SIGNIFICANTLY INHIBITS PANCREATIC
CANCER
IN PRECLINICAL STUDIES—A PATENT HAS BEEN FILED
    * CAN FITE BIOPHARMA LTD - DATA SHOW SIGNIFICANT ANTI-CANCER
EFFECT IN PANCREATIC CARCINOMA
    * CAN FITE BIOPHARMA LTD - CAN-FITE HAS FILED A PATENT
APPLICATION
THAT COVERS USE OF NAMODENOSON FOR TREATMENT OF PANCREATIC
CANCER

Source text for Eikon:  ID:nBw9GHv8Sa 
Further company coverage:  CANF.TA 
 ((Reuters.Briefs@thomsonreuters.com;))